Lee Eva, Lobigs Mario
Division of Immunology and Cell Biology, John Curtin School of Medical Research, Australian National University, Canberra, ACT 0200, Australia.
J Virol. 2002 May;76(10):4901-11. doi: 10.1128/jvi.76.10.4901-4911.2002.
The in vivo mechanism for virulence attenuation of laboratory-derived variants of two flaviviruses in the Japanese encephalitis virus (JEV) serocomplex is described. Host cell adaptation of JEV and Murray Valley encephalitis virus (MVE) by serial passage in adenocarcinoma cells selected for variants characterized by (i) a small plaque phenotype, (ii) increased affinity to heparin-Sepharose, (iii) enhanced susceptibility to inhibition of infectivity by heparin, and (iv) loss of neuroinvasiveness in a mouse model for flaviviral encephalitis. We previously suggested that virulence attenuation of the host cell-adapted variants of MVE is a consequence of their increased dependence on cell surface glycosaminoglycans (GAGs) for attachment and entry (E. Lee and M. Lobigs, J. Virol. 74:8867-8875, 2000). In support of this proposition, we find that GAG-binding variants of JEV and MVE were rapidly removed from the bloodstream and failed to spread from extraneural sites of replication into the brain. Thus, the enhanced affinity of the attenuated variants for GAGs ubiquitously present on cells and extracellular matrices most likely prevented viremia of sufficient magnitude and/or duration required for virus entry into the brain parenchyma. This mechanism may also account, in part, for the attenuation of the JEV SA14-14-2 vaccine, given the sensitivity of the virus to heparin inhibition. A pronounced loss of the capacity of the GAG-binding variants to produce disease was also noted in mice defective in the alpha/beta interferon response, a mouse strain shown here to be highly susceptible to infection with JEV serocomplex flaviviruses. Despite the close genetic relatedness of JEV and MVE, the variants selected for the two viruses were altered at different residues in the envelope (E) protein, viz., Glu(306) and Asp(390) for JEV and MVE, respectively. In both cases the substitutions gave the protein an increased net positive charge. The close spatial proximity of amino acids 306 and 390 in the predicted E protein structure strongly suggests that the two residues define a receptor-binding domain involved in virus attachment to sulfated proteoglycans.
本文描述了日本脑炎病毒(JEV)血清复合体中两种黄病毒实验室衍生变体毒力减弱的体内机制。通过在腺癌细胞中连续传代,使JEV和墨累谷脑炎病毒(MVE)适应宿主细胞,筛选出具有以下特征的变体:(i)小蚀斑表型;(ii)对肝素 - 琼脂糖亲和力增加;(iii)对肝素抑制感染性的敏感性增强;(iv)在黄病毒脑炎小鼠模型中神经侵袭性丧失。我们之前曾提出,MVE宿主细胞适应变体的毒力减弱是其对细胞表面糖胺聚糖(GAGs)附着和进入的依赖性增加的结果(E. Lee和M. Lobigs,《病毒学杂志》74:8867 - 8875,2000)。为支持这一观点,我们发现JEV和MVE的GAG结合变体迅速从血液中清除,且无法从神经外复制部位扩散到大脑。因此,减毒变体对细胞和细胞外基质中普遍存在的GAGs亲和力增强,很可能阻止了病毒进入脑实质所需的足够强度和/或持续时间的病毒血症。鉴于该病毒对肝素抑制的敏感性,这种机制也可能部分解释了JEV SA14 - 14 - 2疫苗的减毒作用。在α/β干扰素反应缺陷的小鼠中也观察到GAG结合变体产生疾病的能力明显丧失,本文显示该小鼠品系对JEV血清复合体黄病毒感染高度敏感。尽管JEV和MVE在基因上密切相关,但两种病毒筛选出的变体在包膜(E)蛋白的不同残基处发生了改变,即JEV为Glu(306),MVE为Asp(390)。在这两种情况下,替换都使蛋白质的净正电荷增加。预测的E蛋白结构中氨基酸306和390在空间上紧密相邻,强烈表明这两个残基定义了一个参与病毒与硫酸化蛋白聚糖附着的受体结合域。